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1. Introduction 
Mitochondria, from the Greek mito (thread) and chondros (grains) are small organelles that 
exist as a network in the cytoplasm of eukaryotic cells, performing a variety of important 
functions including energy production, calcium homeostasis, fatty acid metabolism or heme 
and pyrimidine biosynthesis (Pereira, Moreira et al., 2009). Moreover, mitochondria play a 
critical role in programmed cell death (apoptosis) (Jeong & Seol, 2008; Wang & Youle, 2009). 
Mitochondrial structure comprises two different membranes, the outer (OMM) and the 
inner membrane (IMM)  that functionally separate two distinct compartments, the inter-
membrane space (IMS) and the matrix (Jezek & Plecita-Hlavata, 2009) (Fig. 1). The outer 
membrane encloses mitochondria and it is somewhat identical to other cell membranes, 
including cholesterol in its composition, and is permeable to a large variety of ions and 
metabolites. The inner membrane lacks cholesterol, is rich in the tetra fatty acid-containing 
phospholipid cardiolipin, and basically controls the entry of metabolites and ions into 
mitochondria, through the action of specific transport proteins (Scatena, Bottoni et al., 2007). 
Inner membrane invaginations and membrane enclosed structures which can exist 
connected to the IMM or freely in the mitochondrial matrix are called cristae. It is in these 
latter structures that most of the membrane-bound metabolic proteins and energy-
producing respiratory complexes (complexes I–V) exist (Fig. 1) (Zick, Rabl et al., 2009).  
1.1 Organization and genomics 
Also considered as a reticulum, the mitochondrial network continuously moves, fuses and 
divides in a process tightly regulated by cellular stimuli and disturbances inside this 
organelle (Detmer & Chan, 2007). The shape greatly varies depending on the tissue, 
developmental and physiological state. Within a cell, the distribution of mitochondria is 
unequal depending on the cellular energetic or metabolic demands (Grandemange, 
Herzig et al., 2009). The overall shape of mitochondrial network results from an 
equilibrium between fusion and fission events (Wallace & Fan, 2010). These events allow 
the exchange of organelle contents such as membrane lipids, proteins, solutes, metabolites 
and even mitochondrial DNA (Detmer & Chan, 2007), as well as to provide a balance of 
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the electrochemical gradient (Twig, Graf et al., 2006). Balanced mitochondrial fusion and 
fission is crucial to preserve mitochondrial integrity and functionality (Wallace & Fan, 
2010). Three distinct proteins seem to be involved in mitochondrial fusion: Mitofusins 1 
and 2 (Mfn1 and Mfn2) and Optic Atrophy-1 (OPA-1). Mfn 1 and 2 are GTPases proteins 
that are localized in the OMM and form homo- and hetero-oligomeric complexes between 
themselves and with counterparts in adjacent mitochondria, which mediate their tethering 
(Arnoult, 2007). OPA-1 is a dynamin-related protein that can be found in a soluble form in 
the IMS or tightly associated with the IMM, being a key protein for the fusion of this 
mitochondrial membrane (Arnoult, Grodet et al., 2005). Evidence also suggests that OPA-
1 controls cristae morphology and is implicated in the complete release of cytochrome c 
during apoptosis (Jourdain & Martinou, 2009; Perkins, Bossy-Wetzel et al., 2009). Fusion 
of both membranes is a two-step process that occurs in a coordinate fashion, although the 
precise mechanism remains unclear (Malka, Guillery et al., 2005). Mitochondrial fission 
requires the recruitment of dynamin-related protein 1 (Drp1) from the cytosol to the 
OMM where it forms multimeric rings and spiral-like structures that surround and 
constrict the organelle in a GTP-dependent manner (Sheridan & Martin, 2010). The 
mechanism that triggers this recruitment is still unknown, however, Fis1, a small 
mitochondrial transmembrane protein, seems to be responsible for this mobilization 
(Sheridan & Martin, 2010). 
Mitochondria are the only organelles outside of the nucleus that contain their own genome 
and replicate itself in an independent manner from the nuclear genome. A single DNA 
polymerase (polymerase-gamma), with base excision repair activity, ensures the replication 
of the mitochondrial DNA (mtDNA). Moreover, mtDNA has a particular feature since it is 
exclusively maternally inherited. Each mitochondrion contains approximately 10-15 copies 
of a small circular chromosome that are organized into one or more structures called 
nucleoids. Mitochondrial DNA encodes for 13 proteins that are essential for the electron 
transport and ATP generation by oxidative phosphorylation (OXPHOS) and 2 rRNA and 22 
tRNA (Van Houten, Woshner et al., 2006). The remaining proteins required for 
mitochondrial activity are encoded by the nucleus, synthesized in the cytosol and 
translocated to mitochondria (Wallace, 2008). Mitochondrial DNA undergoes a mutation 
rate that seems to be between 5- to 20- fold higher than what occurs in nuclear DNA 
mutations, although this is not consensual (Malka, Lombes et al., 2006; Scatena, Bottoni et 
al., 2007). The high rate of mutations, if indeed real, can be explained for both the lack of 
mtDNA protective proteins and its proximity to the electron transport chain, where the 
majority of, free-radical production occurs (Fruehauf & Meyskens, 2007). Furthermore, the 
repair mechanism of mitochondrial DNA is less efficient than of nuclear DNA (Berneburg, 
Kamenisch et al., 2006). 
1.2 Oxidative phosphorylation and energy production 
Production of energy within a living cell is performed by the conversion of dietary fats and 
carbohydrates into reducing equivalents. Mitochondria are considered the powerhouses of 
the cell, due to a variety of important energy-producing metabolic pathways in their 
interior. Pyruvate is formed in the cytosol as an end-product of glucose metabolism 
(glycolysis) and can undergo lactic acid or alcoholic fermentation in the absence of oxygen 
(anaerobic conditions). Under aerobic conditions, pyruvate is converted into acetyl 
coenzyme A (acetyl-CoA) by pyruvate dehydrogenase (PDH) in the mitochondrial matrix 




Fig. 1. Mitochondria play a critical role in ATP production, biosynthesis, calcium homeostasis and cell deat
some of the functions referred to in the text: (A) The Krebs cycle occurs in the matrix and supplies reduc
phosphorylation, besides participating as intermediate in several biosynthetic pathways. (B) Overall view 
morphology: The outer mitochondrial membrane (OMM) encloses the organelle within the cell; the inne
(IMM) separates functionally the matrix from the mitochondrial inter-membrane space (IMS). (C) Oxidat
(OXPHOS): electrons from the Krebs cycle are transferred along the respiratory chain. The energy derive
used to pump out protons across the inner membrane at complexes I, III and IV, creating a proton electro
both sides of inner membrane. This electrochemical gradient forms a proton-motive force, which is use t
protons to the matrix through complex V (ATP synthase). A small amount of electrons can leak towards
and complex III due to an one electron transfer reduction of molecular oxygen forming superoxide anion ●






Biosensors for Health, Environment and Biosecurity 
 
414 
Acetyl-CoA enters the Krebs cycle, being oxidized to generate several intermediates 
including NADH and succinate (Fig. 1). Other intermediates of the Krebs cycle are also 
important in several metabolic pathways, including biosynthesis of heme and amino acids 
(Shadel, 2005). Mitochondria can be involved in the -oxidation of fatty acids (Vockley & 
Whiteman, 2002). The end product of this pathway is, once again, Acetyl-CoA, which is 
used in the Krebs cycle. NADH and succinate, among other intermediates that are produced 
by different pathways are oxidized by the electron transport chain, ultimately leading to the 
production of adenosine triphosphate (ATP) in a process known as OXPHOS  (Zick, Rabl et 
al., 2009; Hebert, Lanza et al., 2010)  (Fig. 1). Electrons derived from reduced substrates are 
transferred through several multi-protein complexes (mitochondrial complexes I to IV), 
down their redox potentials and the energy derived from electron transfer is used to pump 
out protons across the IMM at complexes I, III and IV which creates an electrochemical 
gradient between both sides of the IMM. This electrochemical gradient is a proton-motive 
force driving the re-entry of protons towards the matrix through complex V (ATP synthase), 
which is coupled to ATP synthesis (Hebert, Lanza et al., 2010). ATP that is produced is 
exported from the mitochondria by the mitochondrial ADP/ATP translocator (ANT). 
Molecular oxygen is the final electron acceptor in the mitochondrial respiratory chain, which 
is reduced via a sequential four-electron transfer into water by complex IV (cytochrome c 
oxidase, COX). However, some of the electrons that are transferred across the mitochondrial 
electron transport chain can escape and perform a single electron reduction of molecular 
oxygen. This phenomenon occurs continuously even in normal conditions leading to 
formation of superoxide anion (O2●-) and it will be discussed in the next section of this 
chapter. 
1.3 Generation of free radicals  
Among the reactive species that are produced within a living cell, reactive oxygen species 
(ROS) are the most significant. Mitochondrial complexes I and III account for a significant 
proportion of intracellular ROS formation, although complex I is considered the major 
contributor (Adam-Vizi & Chinopoulos, 2006; Soubannier & McBride, 2009).  The 
mitochondrial electron transport chain contains several redox centers, which can react with 
molecular oxygen. As a result, a small amount of electrons leaks from complex I (NADH 
dehydrogenase) and complex III (CoQ cycle), performing a one-electron reduction of 
molecular oxygen that gives rise to superoxide anion (O2●-). Approximately 1-2% of the 
oxygen consumed during OXPHOS under physiological conditions is converted into this 
product (Solaini, Baracca et al., 2010). Superoxide anion produced by respiratory complex I 
is released in the mitochondrial matrix and transformed into hydrogen peroxide (H2O2) 
spontaneously or via manganese superoxide dismutase (MnSOD). In turn, O2●- generated by 
complex III can be released in both sides of the IMM but in the IMS, the dismutation into 
H2O2 is achieved via Cu/Zn-dependent SOD (Cu/ZnSOD). Hydrogen peroxide can be 
converted into water in the mitochondrial matrix by catalase or glutathione peroxidase 
(GSH). Mitochondrial thioredoxin, glutaredoxin and even cytochrome c are other relevant 
ROS scavengers (for a review see (Fruehauf & Meyskens, 2007)). The H2O2 produced can 
also diffuse to the cytosol and trigger the activation of some transcription factors and 
various enzymatic cascades (Cadenas, 2004). General oxidative stress arises when an 
imbalance in the redox steady-state occurs and ROS production exceeds the capacity of the 
cell for detoxification. If H2O2 encounters a reduced transition metal (Fe2+ or Cu2+) or O2●- it 
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can be further reduced in a highly reactive and toxic hydroxyl radical (●OH) by a Fenton or 
Haber-Weiss reaction, respectively (Brandon, Baldi et al., 2006), which is the most potent 
ROS. Although very short-lived, ●OH can damage cellular macromolecules including 
proteins, lipids and nucleic acids. The oxidation of proteins can inactivate and target them 
for degradation; oxidative damage to DNA causes single and double strand-breaks, cross-
link to other molecules and base modifications, while lipid oxidation can generate 
membrane disturbances. As described above, mtDNA represents a critical target of 
oxidative damage since it does not contain histones and it is located in proximity to the 
production site of ROS (Hebert, Lanza et al., 2010). Once damaged, mtDNA can indirectly 
amplify oxidative stress since transcription of critical mitochondrial proteins is defective, 
leading to a vicious cycle of ROS production and eventually triggering cell death. Oxidative 
stress is largely related with aging (Balaban, Nemoto et al., 2005) and is often associated 
with some disorders such as cancer and diabetes (Van Houten, Woshner et al., 2006). 
Reactive nitrogen species (RNS), including nitric oxide and peroxynitrite, can also contribute 
for a regulation of mitochondrial function (especially the former (Brown & Borutaite, 2007)), 
as well for increased mitochondrial damage during pathological conditions (Poderoso, 
2009). 
1.4 Cell death 
Unlike what was thought during several years, cell death is not a process only observed 
when cell tissues are injured by external factors. Actually, cell death is an evolutionary 
conserved and genetically regulated process that is crucial for development, morphogenesis 
and homeostasis in tissues (Martin & Baehrecke, 2004). Programmed cell death (PCD) was 
the first designation attributed to this regulated process. Later, Kerr et al. introduced the 
term apoptosis (Kerr, Wyllie et al., 1972) to designate programmed cell death and these 
designations remain synonymous until now. Cell death was classified into two types: 
apoptosis (programmed cell death) and necrosis (accidental cell death). Nowadays, other 
types of cell death have been identified, including autophagy. Although it has become clear 
that autophagy can work as an adaptive response to nutrient starvation, cell death can occur 
due to autophagy over-stimulation (Rami, 2009). Autophagy is a spatially restricted 
phenomenon characterized by the absence of chromatin condensation and in which parts of 
the cytoplasm are engulfed by specialized double membrane vesicles, so-called 
autophagosomes, and digested by lysosomal hydrolases (Ulivieri, 2010). Mitophagy is a 
specific autophagic elimination of mitochondria, identified in yeast and mammals and 
regulated by PINK-1, among others (Youle & Narendra, 2011). However, if for some reason 
the clearing of old/damaged mitochondria is insufficient, a malignant transformation may 
occur (Morselli, Galluzzi et al., 2009). Necrotic cell death is characterized by a moderate or 
null chromatin condensation and by an increase in cell volume that culminates in loss of 
plasma membrane integrity and swelling of cytoplasmic organelles (Galluzzi, Maiuri et al., 
2007). The disruption of cell membranes leads to the release of cell contents usually resulting 
in local inflammatory reactions and damage to contiguous cells. Several studies have 
already demonstrated that mitochondria can be involved in this type of cell death due to a 
phenomenon called mitochondrial permeability transition (MPT), which results from the 
opening of unspecific protein pores in the IMM. The MPT results in dissipation of 
mitochondrial membrane potential (∆) and leads to an uncoupling of OXPHOS and 
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decreased ATP, leading cells to necrosis (Sharaf El Dein, Gallerne et al., 2009; Zorov, 
Juhaszova et al., 2009). Apoptosis is the best-studied modality of cell death and plays an 
essential role in the maintenance of homeostasis by eliminating damaged, infected or 
superfluous cells in a regulated form that minimizes inflammatory reactions and damage to 
neighboring cells (Jeong & Seol, 2008; Schug & Gottlieb, 2009; Sheridan & Martin, 2010). 
Apoptotic imbalance may contribute to the development of neurodegenerative disorders, 
autoimmune disorders, cancer or even viral infections (Arnoult, 2007; Jourdain & Martinou, 
2009). Apoptotic cells exhibit specific changes, including chromatin condensation, nuclear 
fragmentation, and plasma membrane blebbing. The late stages of apoptosis are 
characterized by fragmentation of the cell-membrane into vesicles called apoptotic bodies 
which contain intact cytoplasmatic organelles or nuclear fragments. These vesicles are 
recognized by the immune system macrophages, preventing inflammatory responses 
(Martin & Baehrecke, 2004; Jeong & Seol, 2008; Tait & Green, 2010). There are two main 
pathways by which a cell can engage apoptosis: the extrinsic (or cell death receptor-
mediated) apoptotic pathway and intrinsic (or mitochondrial-mediated) apoptotic pathway 
(Tait & Green, 2010) (Fig. 2). In both pathways, the apoptotic process is driven by a family of 
cysteine proteases that are expressed as pro-enzymes and are activated by proteolysis. 
These proteases, known as caspases, specifically cleave their substrates at aspartic residues 
and are categorized into initiators (such as caspases -8 and -9) and effectors or executioners 
(such as caspases -3 and -7) (Arnoult, 2007; Jeong & Seol, 2008). Mitochondria are central 
players in the intrinsic apoptotic pathway; in fact, mitochondria retain a pool of pro-
apoptotic factors in the IMS. During the development of the intrinsic pathway, pores are 
formed in the OMM in a process called outer mitochondrial membrane permeabilization 
(OMMP, different from the mitochondrial permeability transition). The OMMP results in the 
release of pro-apoptotic factors, such as cytochrome c and the apoptotic-inducing factor, 
AIF, to the cytosol (Saelens, Festjens et al., 2004; Sheridan & Martin, 2010).  Although the 
effects of pro-apoptotic factors that are released in the cytosol are well characterized, the 
mechanisms underlying the OMMP remains controversial (Martinou & Green, 2001) and 
there are currently several mechanisms that have been proposed. One of these mechanisms 
involves members of Bcl-2 proteins family, which comprises three subgroups; the anti-
apoptotic family members such as Bcl-2 and Bcl-xL, the pro-apoptotic Bax/Bak sub-family 
and the pro-apoptotic BH3-only proteins such as Bim, Bad, Bid, Puma and Noxa. BH3-only 
proteins links cell death signals to mitochondria, where the interplay between various 
members of the Bcl-2 family determines the fate of the cell (Martinou & Green, 2001; Wong 
& Puthalakath, 2008). A mild change in the dynamic balance of these proteins may result 
either in inhibition or exacerbation of cell death. The intrinsic and extrinsic pathways can 
interact with each other at the mitochondrial level where signal amplification occurs (Fig. 2) 
(Saelens, Festjens et al., 2004). 
2. Mitochondria and disease 
As it was discussed in the previous sections, mitochondria are organelles with crucial 
importance in cell bioenergetics, signaling and survival, among others. Mitochondrial 
dysfunction is associated with several diseases, as it will be discussed in the present 
section. 
www.intechopen.com




Fig. 2. An overview of the extrinsic and intrinsic pathways of apoptosis. The intrinsic and 
extrinsic pathways can crossroad in mitochondria, which leads to signal amplification. IMM, 
inner mitochondrial membrane; IMS, intermembrane space; OMM, outer mitochondrial 
membrane. Figure adapted from (Pereira, Moreira et al., 2009), with permission. 
2.1 Cancer 
As described above, the impact of mitochondria on cellular physiology is not limited to ATP 
production. Due to the importance of mitochondria for cellular functions and cell fate, the 
role of these small organelles in cancer cell biology is becoming increasingly recognized.  
The first suggestion about the role of mitochondria in tumor metabolism appeared in 1920’s, 
when Otto Warburg observed increased glycolysis in tumor cells, even in the presence of 
abundant oxygen. Following this observation, Warburg hypothesized that tumor cells tend 
to obtain most of their energy through aerobic glycolysis (Warburg, 1930). This 
phenomenon, known as the Warburg effect, is considered one of the major metabolic 
alterations observed during cancer development (Warburg, 1956). Since then, several 
hypotheses have been suggested in order to explain the aerobic glycolysis observed in some 
(but not all) cancer cells. An irreversible respiratory impairment was first proposed by 
Warburg (Warburg, 1956). In fact, the author suggested that the origin of cancer cells was in 
an irreversible damage to the respiration apparatus (Warburg, 1956). However, Warburg 
results were questioned when Boyland observed an increase in respiration after addition of 
succinate or fumarate to tumor slices (Boyland & Boyland, 1936). Also, it was described that 
neoplasias can have a normal oxidative phosphorylation capacity when supplemented with 
NAD+ (Wenner & Weinhouse, 1953). More recently, it was demonstrated that oxidative 
phosphorylation can be improved in cancer cells by changing substrate availability 
(Rossignol, Gilkerson et al., 2004). Despite all the arguments against the hypotheses raised 
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by Warburg, the truth is the Warburg effect was an important discovery that allowed for an 
important progress in cancer research and prognosis (Ak, Stokkel et al., 2000). Being 
mitochondria the organelle where several cellular metabolic reactions occur and where the 
majority of cellular energy is produced, the role of mitochondria in cancer development is 
indubitable. For example, mutations in mitochondrial and nuclear genes encoding proteins 
involved in oxidative phosphorylation have been observed in several cancers, suggesting a 
role for defective mitochondrial oxidative phosphorylation in tumorigenesis (for a review 
see (Chandra & Singh, 2010)). Mutations can be acquired during or after oncogenesis and 
result in an inhibition of oxidative phosphorylation, increased ROS production, tumor cells 
proliferation and adaptation to tumor microenvironments (Hung, Wu et al., 2010; Lee, 
Chang et al., 2010). Also, decreased mtDNA copy number has been associated with 
resistance to apoptosis and increased invasiveness (Chandra & Singh, 2010). The loss of 
function of mitochondrial-specific enzymes, such as succinate dehydrogenase and 
fumarate dehydrogenase, results in the accumulation of specific metabolites in the 
cytosol, that can favor the activation of transcription factors (eg. hypoxia-inducible factor, 
HIF), directing the metabolism to aerobic glycolysis (Yeung, Pan et al., 2008; Bellance, 
Lestienne et al., 2009; Marin-Hernandez, Gallardo-Perez et al., 2009) establishing a 
possible correlation between mitochondrial alterations and the Warburg effect observed 
in cancer cells. 
2.2 Mitochondrial DNA diseases 
Besides the nucleus, mitochondria have their own functional genome (Reich & Luck, 1966). 
Mutations in mtDNA are associated with the development of different pathologies. 
Although the mtDNA of an individual is usually identical in all cell types (homoplasmy), 
variations may occur, causing dissimilarities between wild type and mutant mtDNA 
(heteroplasmy). Progressive accumulation of mutant mtDNA in affected tissue will increase 
the severity of the phenotype associated with those mutations. Besides the rate of 
heteroplasmy, the age, gender and environment clearly contribute for the high diversity of 
phenotypes (McFarland, Taylor et al., 2002). The so-called mitochondrial diseases are caused 
by mutations in mtDNA or in nuclear genes that codify for proteins involved in the 
mitochondrial respiratory chain or in overall mitochondrial biology. For the sake of 
simplicity, we will focus now in diseases that are the result from mtDNA mutations. The 
degree of severity of mtDNA alterations and the impact on organ phenotype is determined 
by the threshold effect, or in other words, the dependency of the organ on the mutated 
protein, or on the mitochondrial function itself (Dimauro & Davidzon, 2005). Simplifying, 
this means that organs that are more dependent on energy will be first affected by 
alterations of mitochondrial function caused by mtDNA mutations (Rossignol, Faustin et al., 
2003). Mitochondrial DNA diseases can be divided in two main categories based on the 
genomic origin of the disorder: 1) syndromes due to mtDNA rearrangements or 2) 
syndromes based on mtDNA point mutations. Kearns-Sayre (KSS) and Person Marrow-
Pancreas Syndromes are classical examples of disorders associated with mtDNA 
rearrangements. KSS is characterized by external progressive opthalmoplegia and 
pigmentary retinopathy and is associated with heteroplasmatic mtDNA deletions. Pearson 
Marrow-Pancreas Syndrome is commonly diagnosed during infancy or postmortem and is 
caused by deletions or duplications in mtDNA. It is rarely diagnosed during pregnancy, but 
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should be suspected in the presence of severe anemia or lactic acidosis (Morel, Joris et al., 
2009). Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes 
(MELAS) is a multisystem mitochondrial maternally inherited disease. It is caused by a 
point mutation characterized by a A to G transition at the position 3260 of the mitochondrial 
genome. It is normally associated with frequent episodes of migraine and intraventricular 
conduction disturbances and syncopal episodes based on paroxysmal atrioventricular block 
have been found already (Connolly, Feigenbaum et al., 2010). Leigh Syndrome is a maternal-
inherited point mutation in polypeptide-encoding genes based disorder. Although still 
largely unknown, it is suggested that the Leigh Syndrome is caused by defects in genes 
coding for the pyruvate dehydrogenase complex, cytochrome c oxidase, ATP synthase 
subunit 6 or complex I subunits (Quintana, Kruse et al.; Naess, Freyer et al., 2009; Quintana, 
Mayr et al., 2009). 
2.3 Diabetes 
Diabetes mellitus (DM) is a metabolic disease characterized by hyperglycemia and 
alterations in carbohydrate, lipid and protein metabolism due to disturbances in insulin 
secretion, having as a long-term consequence, the failure in several organs. As in previous 
cases, mitochondrial multi-tasking suggests an important role of this organelle not only in 
the pathogenesis of this condition, but also in the development of long-term complications. 
Several mitochondrial alterations have been described during the progress of diabetes 
mellitus, including respiratory alterations and altered induction of the MPT (reviewed in 
(Oliveira, 2005)). Besides the heart (Oliveira, Rolo et al., 2001; Oliveira, Seica et al., 2003; 
Santos, Palmeira et al., 2003; Bugger & Abel, 2011), alterations of mitochondrial function 
have been recorded in liver (Ferreira, Seica et al., 2003), kidney (Oliveira, Esteves et al., 
2004), brain (Moreira, Santos et al., 2004) and testis mitochondria (Palmeira, Santos et al., 
2001; Amaral, Oliveira et al., 2008; Amaral, Mota et al., 2009), which show a multi-organ 
scope of hyperglycaemia-induced mitochondrial alterations. Oliveira et al. demonstrated 
that streptozotocin (STZ)-induced diabetes results in inhibition of cardiac mitochondrial 
respiration and increased susceptibility to calcium-induced MPT (Oliveira, Seica et al., 2003). 
In theory, this means that heart mitochondria from diabetic animals are less able to 
withstand a metabolic stress, mimicked in this work by the addition of ADP and calcium. 
Interestingly, heart mitochondria from Goto-Kakizaki (GK) rats have decreased 
susceptibility to the MPT (Oliveira, Rolo et al., 2001). GK rats are an animal model for non-
obese type 2 diabetes, developing hyperglycaemia earlier in life, suggesting that the 
severity/duration of the hyperglycaemic period is important for cardiac mitochondrial 
alterations. Interestingly, different alterations in terms of hepatic mitochondrial respiratory 
activity were found in both STZ-treated and GK rats, such alterations being modulated by 
the age of the animals (Ferreira, Palmeira et al., 2003; Ferreira, Seica et al., 2003). Alterations 
in MPT induction are also widespread to other tissues. Lumini-Oliveira et al. reported that 
18 weeks of STZ treatment lead to a decrease in gastrocnemius mitochondrial respiratory 
control ratio and to decreased calcium-dependent MPT, which may counteract the negative 
effects of hyperglycaemia. It is still unclear what may cause mitochondrial alterations 
during the course of diabetes and why such alterations appear to be organ and age-specific. 
Increased oxidative stress due to increased mitochondrial generation of ROS and/or 
depression of mitochondrial antioxidant defenses may be an attractive mechanism 
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(Kucharska, Braunova et al., 2000; Turko, Li et al., 2003; Kowluru, Atasi et al., 2006; Ren, Li 
et al., 2008; Munusamy & MacMillan-Crow, 2009). A growing body of evidence also 
suggests that mitochondrial dysfunction in pancreatic beta-cells may be also one of the 
initiation factors responsible for depressed insulin release (Mulder & Ling, 2009). In fact, 
mitochondria in beta-cells have a critical role in the release of insulin. Beta cell mitochondria 
play a key role in this process, not only by providing ATP to support insulin secretion when 
required, but also by synthesizing metabolites that can couple glucose sensing to insulin 
exocytosis. ATP alone or possibly modulated by several coupling factors, triggers closure of 
the ATP-sensitive potassium channel, resulting in membrane depolarization that increases 
intracellular calcium and insulin secretion (Liu, Okada et al., 2009; Jitrapakdee, 
Wutthisathapornchai et al., 2011). In several models for diabetes, mitochondrial defects in 
beta-cells have been found (reviewed in (Maechler, Li et al., 2011)), including altered 
expression of the voltage-dependent anion-channel (Ahmed, Muhammed et al., 2011) and 
altered respiratory activity and oxidative stress (Lu, Koshkin et al., 2011). In beta-cell 
mitochondria, increased oxidative stress may be critically important in the pathogenesis of 
the disease (Nishikawa & Araki, 2007), although what exactly leads to that is still a matter of 
debate. What is interesting is that some forms of diabetes are originated by defects on 
mitochondrial DNA, present in pancreatic beta-cells (de Andrade, Rubi et al., 2006; 
Mezghani, Mkaouar-Rebai et al., 2011). Other mitochondrial-relevant alterations in beta-cells 
include enhanced apoptosis in some forms of auto-immune type I and type II diabetes 
(Johnson & Luciani, 2011). 
3. Drug-induced mitochondrial toxicity 
Toxic compounds can interfere and modify physiological mechanisms, leading to cell 
alterations and ultimately damage. In many cases of drug-induced toxicity, mitochondria 
are the preferential target for toxic compounds and one important initiator of cell damage. 
In this section, we will focus on the present knowledge regarding the mechanism of action 
of some selected drugs, whose mechanism of toxicity has a clear mitochondrial component. 
3.1 Anti-cancer drugs 
For five decades, anthracycline antibiotics have played an important role in the treatment of 
a variety of cancer types, due to their efficacy and broad spectrum of activity (Sawyer, Peng 
et al., 2010). The anti-tumor activity of anthracyclines is based on their ability to intercalate 
DNA and to inhibit enzymes involved in DNA replication and transcription such as 
topoisomerase II and RNA polymerases, respectively (Sawyer, Peng et al., 2010). 
Disturbance of DNA function is thought to be the main responsible for tumor cell death, a 
typical behavior shared by other anti-cancer drugs (Singal, Iliskovic et al., 1997). However, 
anthracycline therapy is associated with significant side effects, including cardiotoxicity 
(Chen, Peng et al., 2007; Sawyer, Peng et al., 2010). A particular leading drug of this group, 
Doxorubicin (DOX), has been intensively studied and rapidly stood out from other analog 
molecules due to its efficacy.  Unfortunately, its cardiotoxicity also stood out, although the 
molecular mechanisms are still far of being completely understood (Arola, Saraste et al., 
2000; Horenstein, Vander Heide et al., 2000). The onset of DOX-induced cardiomyopathy is 
characterized by several forms of tachycardia (Bristow, Minobe et al., 1981), altered left 
ventricular function (Hrdina, Gersl et al., 2000), and severe histological changes such as 
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vacuolization of the cytoplasm, loss of myofibrils, altered sarcoplasmic reticulum, 
deposition of lipid droplets, and mitochondrial swelling (Lefrak, Pitha et al., 1973; Olson & 
Capen, 1978; Iwasaki & Suzuki, 1991; Sardao, Oliveira et al., 2009). More evidence suggests 
that mitochondria are a critical target in the development of DOX-induced cardiomyopathy 
(Yoon, Kajiyama et al., 1983; Praet & Ruysschaert, 1993; Jung & Reszka, 2001; Wallace, 2003; 
Berthiaume & Wallace, 2007). Numerous mechanisms for the toxicity of DOX on cardiac 
mitochondrial function have been proposed, such as generation of free radicals (Muraoka & 
Miura, 2003), interaction with mitochondrial DNA (L'Ecuyer, Sanjeev et al., 2006), 
disruption of cardiac gene expression (Berthiaume & Wallace, 2007), alteration of calcium 
homeostasis (Lebrecht, Kirschner et al.), lipid peroxidation mediating disturbance of 
mitochondrial membranes (Mimnaugh, Trush et al., 1985), and inhibition of mitochondrial 
respiration chain, decreasing both intracellular ATP and phosphocreatine (PCr) (Tokarska-
Schlattner, Zaugg et al., 2006). DOX can also interfere with mitochondrial function in other 
targets, including by inhibiting phosphorylation steps (Marcillat, Zhang et al., 1989) or by 
exerting partial uncoupling (Bugger, Guzman et al.). Although several hypotheses have 
been proposed to explain cardiac DOX toxicity, oxidative stress is the most widely accepted; 
in fact, data from the literature indicate that the cardiac tissue is particularly susceptible to 
free radicals due to reduced levels of enzymatic antioxidants defenses when compared with 
other tissues (Hrdina, Gersl et al., 2000). DOX is able to increase ROS through both an 
enzymatic mechanism involving a redox cycle and cellular oxidoreductases such as NADH 
dehydrogenase of complex I or cytochrome P-450 reductase, and through a non-enzymatic 
pathway involving complexes with iron (Fe3+) (Davies & Doroshow, 1986; Doroshow & 
Davies, 1986; Jung & Reszka, 2001; Minotti, Recalcati et al., 2004). DOX-induced oxidative 
stress can also be related with induction of the MPT (Ascensao, Lumini-Oliveira et al.; Zhou, 
Starkov et al., 2001; Oliveira, Santos et al., 2006; Oliveira & Wallace, 2006), which is observed 
in both in vivo and in vitro studies (Pereira & Oliveira, 2010). In vitro, DOX-induced MPT 
pore opening results in mitochondrial depolarization, respiratory inhibition, matrix 
swelling, pyridine nucleotides depletion and release of intermembrane proteins, including 
cytochrome c (Oliveira, Bjork et al., 2004; Berthiaume, Oliveira et al., 2005; Oliveira, Santos et 
al., 2006).  
3.2 Nucleoside-analog reverse transcriptase inhibitors 
Nucleoside reverse transcriptase inhibitors (NRTIs), a class of anti-retroviral drugs, are 
specifically prescribed as a therapy to Acquired Immune Deficiency Syndrome (AIDS). 
Several studies indicate that these drugs induce mitochondrial toxicity by interfering with 
mitochondrial DNA (mtDNA) synthesis (Lund & Wallace, 2004; Lewis, Kohler et al., 2006). 
The targets of NRTIs are reverse transcriptase enzymes but due to the similarities with 
substrates for the mitochondrial enzyme DNA polymerase-gamma, NRTIs also inhibit this 
mitochondrial enzyme, affecting mtDNA copy number (Lewis, Simpson et al., 1994). As 
described above, mitochondrial DNA depletion may be clinically manifested in one or 
several main targets tissues, depending on the energy requirements of that same tissue 
(Rossignol, Faustin et al., 2003). Liver mitochondrial complications as hepatomegaly and 
increased lipid deposits have been primarily observed with dideoxynucleosidesdidanosine, 
stavudine, and zalcitabin. mtDNA depletion has been demonstrated in the liver of HIV 
patients, with each of dideoxynucleosides inducing a time- and concentration-dependent 
mtDNA depletion (Walker, Bauerle et al., 2004). Several NRTIs were shown to directly 
interfere with cardiac mitochondrial respiratory chain decreasing membrane potential and 
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decreasing mitochondrial calcium buffer capacity (Lund & Wallace, 2004). Zidovudine 
(AZT) is the most well-known antiviral and its side effects have been subject of several 
studies focused on studying mitochondrial interactions (Lewis, Simpson et al., 1994). 
Competitive inhibition of thymidine phosphorylation (Lynx, Bentley et al., 2006; Lynx & 
McKee, 2006), induction of superoxide anion formation (Szabados, Fischer et al., 1999; de la 
Asuncion, Del Olmo et al., 2004), inhibition of adenylate kinase activity (Barile, Valenti et al., 
1994), and inhibition of the ANT both in heart (Valenti, Barile et al., 2000) and liver (Barile, 
Valenti et al., 1997) are some of the effects observed in isolated mitochondria incubated with 
AZT and other NRTIs. Inhibition of phosphate transport in rat heart mitochondria by AZT 
was found to be related with increased superoxide anion production, as shown by the 
protective effects of several ROS scavengers (Valenti, Atlante et al., 2002). Oxidative stress 
probably plays the most important role in AZT-induced mitochondrial dysfunction. Indeed, 
a 2-week treatment of rats with AZT leads to increased ROS and peroxynitrite production 
and induced single-strand DNA breaks (Szabados, Fischer et al., 1999). Lipid peroxidation 
and oxidation of cell proteins, determined from protein carbonyl content, increased as a 
consequence of AZT treatment (Szabados, Fischer et al., 1999). Depletion of mitochondrial 
glutathione was also found in mitochondria isolated from the hearts of AZT-treated rats (de 
la Asuncion, Del Olmo et al., 2004). Furthermore, NRTIs are able to indirectly inhibit the 
regulation of mitochondrial complex I by cyclic adenosine monophosphate (cAMP). This 
type of inhibition may explain disturbances observed in many patients regarding ROS 
production, NADH/NAD+ ratio, and high lactate levels (Lund & Wallace, 2008). 
3.3 Anti-diabetic agents 
Treatment of hyperglycemia during diabetes involves the use of hypoglycemic drugs. 
Initially, biguanide agents such as metformin, phenformin and buformin were used for the 
management of hyperglycemia in type 2 diabetes mellitus (T2D). However, these anti-
diabetic drugs rapidly resulted into a number of serious adverse effects, which made the 
pharmacological management of hyperglycemia still a challenge to the clinic. 
Both buformin and phenformin were withdrawn from the market in the 1970´s due to high 
incidence of lactic-acidosis-associated mortality and gastrointestinal symptoms, although 
phenformin is still available in some countries. Metformin is now believed to be the most 
widely prescribed anti-diabetic drug in the world (Correia, Carvalho et al., 2008). The anti-
diabetic effect of metformin and phenformin and increased lactic acidosis observed during 
treatment are suggested to result from a single mechanism, the inhibition of  mitochondrial 
complex I (El-Mir, Nogueira et al., 2000; Correia, Carvalho et al., 2008). Other investigators 
described that inhibition of hepatocyte complex I not only caused not only a reduction of 
blood glucose levels in human subjects but also a complete inhibition of hepatic 
gluconeogenesis, a metabolic process that is significantly increased in T2D contributing to 
the observed fasting hyperglycemia (Hundal, Krssak et al., 2000). In intact cells, metformin 
increases AMP-activated protein kinase (AMPK) activity, resulting in increased fatty acid 
oxidation, down-regulation of lipogenic genes, decreased hepatic glucose production and 
stimulation of glucose uptake (Zhou, Myers et al., 2001). Beyond biguanides, 
thiazolidinediones (TZD) is a class of oral antihyperglycemic drugs also known as 
glitazones that have been used as an auxiliary therapy for diabetes mellitus (Petersen, 
Krssak et al., 2000; Mudaliar & Henry, 2001). Glitazones includes troglitazone, rosiglitazone, 
and pioglitazone, which are used to ameliorate hyperglycemia by increasing insulin-
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stimulated glucose removal by skeletal muscle (Petersen, Krssak et al., 2000; Mudaliar & 
Henry, 2001).  Indeed, TZDs can also be considered insulin sensitizers because they are able 
to lower glucose levels in models of insulin resistance without increasing pancreatic insulin 
production (Kliewer, Xu et al., 2001). The ability of TZD to lower serum glucose levels and 
promote an increase in glucose utilization by accelerating glycolytic flux, can lead to 
excessive lactic acid production. Although lowering glucose efficiently is considered a 
desired effect of TZD, lactic acidosis seems to be a compensatory mechanism to a decrease in 
mitochondrial generated ATP, something that is often observed in diabetic individuals. 
These drugs are known to bind and activate the nuclear peroxisome proliferation receptor γ 
(PPARγ), and interestingly to also inhibit mitochondrial complex I. The efficacy of TZD to 
inhibit complex I or to cause lactate release in skeletal muscle or rat liver homogenates 
follows the sequence troglitazone, rosiglitazone, and metformin, being the latter less 
efficient (Brunmair, Staniek et al., 2004). Several studies reveal that TZDs may increase the 
risk of heart failure (Delea, Edelsberg et al., 2003; Karter, Ahmed et al., 2004), which limits 
their clinical application. The risk for heart failure may lie on mitochondrial impairment as 
consequence of TZD toxicity.  In this case, disruption of NADH oxidation by mitochondrial 
complex I tends to occur, although the toxicity effect may also be the mechanism for the 
pharmacological benefits observed (Scatena, Martorana et al., 2004). This means the border 
line between a desired pharmacological effect and a toxic consequence is very blurred, and 
in fact, long-term and/or large-scale inhibition of complex I activity can lead to ATP 
depletion, oxidative burst and ultimately cell death (Li, Ragheb et al., 2003). An example of 
TZD which had high impact in the clinic is troglitazone (TRO), introduced in 1997 but soon 
withdrawn from the market because of reports of serious hepatotoxicity, receiving a black 
box warning from the U.S. Food and Drug Administration (FDA). In fact, TRO, when 
incubated with HepG2 cells, decreased cellular ATP and  (Tirmenstein, Hu et al., 2002; 
Bova, Tam et al., 2005). Lim et al. also demonstrated that TRO increases intramitochondrial 
oxidative stress that activates the Trx2/Ask1 pathway, leading to mitochondrial 
permeabilization (Lim, Liu et al., 2008). More recently, data indicate that significant mtDNA 
damage caused by TRO is a prime initiator of the hepatoxicity caused by this drug (Rachek, 
Yuzefovych et al., 2009). Overall, the data suggest that the reported mitochondrial effects of 
anti-diabetic drugs, especially complex I inhibition are worth of further attention, not only 
to explain some of its pharmacological effects but also to predict safety during drug 
development. 
3.4 Anti-depressant agents 
Tricyclic antidepressants (TCAs) are heterocyclic chemicals discovered in the early 1950s 
and which have been primarily used to relieve depressive symptoms. Fluoxetine (Prozac), 
an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class, presents some 
cardiovascular side effects and drug-drug interactions. Interestingly, some studies show that 
fluoxetine indirectly affects electron transport and F1Fo-ATPase activity inhibiting OXPHOS 
in isolated rat brain and liver mitochondria (Souza, Polizello et al., 1994; Curti, Mingatto et 
al., 1999). The results obtained by Curti et al., suggested that these effects are mediated by 
the drug interference with the physical state of lipid bilayer of the IMM (Curti, Mingatto et 
al., 1999). In turn, nefazodone is a TCA with a more favorable side effect profile when 
compared to fluoxetine and even with other drugs commonly used to mitigate depressive 
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conditions. Nefazodone was initially considered very advantageous among several other 
TCAs (Davis, Whittington et al., 1997). Initially, the incidence of specific organ toxicity was 
considered very low, and related fatalities by severe toxicity were non-existent on several 
hundred of patients during long periods of treatment (Lader, 1996; Robinson, Roberts et al., 
1996; Davis, Whittington et al., 1997). Among other physiological advantages, nefazodone 
had the ability to treat some patients who did not respond to other TCAs (Ellingrod & Perry, 
1995; Robinson, Roberts et al., 1996). However, some cardiovascular complications such as 
asymptomatic reduced systolic blood pressure and asymptomatic sinus bradycardia, started 
to be detected and considered as markers for cardiotoxicity (Robinson, Roberts et al., 1996). 
Despite the possible therapeutic advantages, the drug was withdrawn from the U.S. market 
in 2004, based on cardiotoxicity and later on some severe cases of adverse hepatoxicity as 
well. Indeed, more recent data show that when compared to buspirone, nefazodone is more 
toxic to hepatic mitochondrial function (Dykens, Jamieson et al., 2008). Dykens et al. 
demonstrated that nefazodone promoted inhibition of mitochondrial respiration and 
increased glycolysis in isolated rat liver mitochondria and in intact HepG2 cells, respectively 
(Dykens, Jamieson et al., 2008). Two other anti-depressant drugs, amineptine and tianeptine, 
can also lead to hepatitis associated with microvesicular steatosis, in fact, their heptanoic 
acid side chain may be responsible for reversibly inhibiting mitochondrial fatty acid 
oxidation by a competitive mechanism (Fromenty, Freneaux et al., 1989). 
3.5 Statins and fibrates 
Statins (or HMG-CoA reductase inhibitors) are a class of drugs used to decrease cholesterol 
levels by inhibiting the enzyme HMG-CoA reductase, which plays a central role in the 
production of cholesterol in the liver. Statins are generally safe and well tolerated, but the 
major side effect, which occurs in about 1% of patients, is skeletal myopathy (Davidson, 
2001). Interestingly, many congenital myopathies are associated with defects in 
mitochondrial enzymes (Cornelio & Di Donato, 1985; Wallace, 2000) and bio-accumulation 
of statins by fast twitch skeletal muscle cells can increase the risk of mitochondrially-
induced rhabdomyolysis (Westwood, Bigley et al., 2005).  Several reports describe acute 
effects of statins on skeletal muscle mitochondria. Lovastatin and simvastatin were reported 
to induce the MPT in vitro and decrease the content of total membrane thiol groups in 
mitochondria isolated from mouse hind limb (Velho, Okanobo et al., 2006). Mitochondrial 
degeneration was observed on rat skeletal muscle fibers treated with cerivastatin (Seachrist, 
Loi et al., 2005). A variety of other statins are known to induce the MPT leading to 
irreversible collapse of the transmembrane potential and release of pro-apoptotic factors 
(Cafforio, Dammacco et al., 2005; Kaufmann, Torok et al., 2006), in a Bcl-xL-preventable 
manner (Blanco-Colio, Justo et al., 2003). Kaufman and colleagues also reported inhibition of 
-oxidation and swelling of isolated skeletal muscle mitochondria by statins (Kaufmann, 
Torok et al., 2006). Ubiquinone coenzyme Q10 (CoQ10) depletion is another hypothetic 
contributor to statin-induced myopathy (Folkers, Langsjoen et al., 1990). Thus, CoQ10 
depletion can contribute to mitochondrial dysfunction leading to statin-induced myopathy 
since CoQ10 acts as an electron carrier in the mitochondrial respiratory chain (Schaars & 
Stalenhoef, 2008). Besides the effects on skeletal muscle, lovastatin and simvastatin inhibit 
mitochondrial respiration of isolated liver mitochondria by a direct effect on complexes II, 
III, IV and V (Nadanaciva, Dykens et al., 2007). Fibrates, in turn, are used as accessory 
therapy in many forms of hypercholesterolemia, usually in combination with statins 
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(Steiner, 2007). Fibrates are structurally related to the thiazolidinediones, and 
pharmacologically act on PPARγ, impairing mitochondrial function (Barter & Rye, 2006). 
In an ex vivo experiment with isolated mitochondria, fenofibrate inhibits complex I 
activity and disturbs rat mitochondrial function (Brunmair, Lest et al., 2004). The fibrates 
ciglitizone, bezafibrate, gemfibrozil, and clofibric acid were reported to increase lactate 
and acetate levels due to increase anaerobic glycolysis and fatty acid beta-oxidation, to 
inhibit NADH-cytochrome c reductase activity, and show a correlation between 
mitochondrial toxicity and inhibition of HL-60 cell growth (Scatena, Martorana et al., 
2004). In opposition, Scatena et al. argued that fibrates induce toxicity by disrupting 
mitochondrial function through a mechanism partly independent on PPARs (Scatena, 
Bottoni et al., 2004). 
4. Environmental pollutants 
Humans are daily exposed to a variety of molecules, which can be present in food, 
beverages and even in the atmosphere. Although most are harmless, either due to their 
intrinsic safety or to the decreased exposure levels, the truth is that some of those molecules 
disturb several biological systems, including mitochondria, leading to short or long-term 
organ toxicity (Wallenborn, Schladweiler et al., 2009). 
Heavy metal toxicity is widespread in the world due to the very large amount of industrial 
activities that release these compounds in nature. Heavy metal toxicity can have different 
aspects and result into different pathologies, including carcinogenesis and vascular diseases 
(Nash, 2005). As expected, the toxicity of heavy metals also impacts mitochondria. 
Cadmium, for example, which has been associated with learning impairments and 
neurological disorders, has been described to cause mitochondrial-dependent apoptosis in 
oligodendrocytes (Hossain, Liu et al., 2009) and in a skin cell line (Son, Lee et al., 2011). 
Cadmium accumulation in the kidney involves alteration of mitochondrial function, which 
results into increased generation of mitochondrial free radicals (Gobe & Crane, 2011), 
similarly to what occurs in other target organs (Cannino, Ferruggia et al., 2009). As 
expected, cadmium, similarly to as mercury and copper, induces the MPT, resulting in 
mitochondrial swelling and activation of basal respiration, as well as in membrane 
depolarization (Belyaeva, Glazunov et al., 2004). Mercury also caused apoptosis in several 
biological models by interfering with mitochondrial function (Shenker, Guo et al., 1998). In 
fact, low concentrations of methylmercury cause inhibition of mitochondrial function, which 
progresses to apoptotic cell death (Carranza-Rosales, Said-Fernandez et al., 2005). 
Mitochondrial respiration in hepatoma AS-30D cells is initially uncoupled for lower 
concentrations and progressively inhibited for higher concentrations, resulting also in 
increased generation of ROS (Belyaeva, Dymkowska et al., 2008). Although in this same 
model, copper (Cu2+) was not as toxic (Belyaeva, Dymkowska et al., 2008), other works have 
shown that copper causes toxicity in astrocytes, due to increased MPT induction and 
oxidative stress (Reddy, Rao et al., 2008). Also, copper decreased , followed by apoptosis 
in MES23.5 dopaminergic cells (Shi, Jiang et al., 2008). Interestingly, at least a significant part 
of copper toxicity in non-human species can also be explained by inhibition of 
mitochondrial function, including activation of the MPT, as observed in trout hepatocytes 
(Krumschnabel, Manzl et al., 2005). Iron has been considered a significant pro-oxidant metal 
due to its role in the formation of hydroxyl radical via Fenton reactions (Stohs & Bagchi, 
1995). Although iron is essential for life, it can pose serious health risks with the liver being 
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the most relevant target. Heavy iron overload, as described during primary (hereditary) or 
secondary forms of hemochromatosis, may cause cirrhosis, liver failure, and hepatocellular 
carcinoma (Bonkovsky & Lambrecht, 2000). In addition, iron can contribute to the 
development or progression of alcoholic liver disease, nonalcoholic liver steatohepatitis, 
chronic viral hepatitis and prophyria cutanea tarda, among other diseases (Bonkovsky & 
Lambrecht, 2000). In thalassemia major, one of the clinical end-points is an iron overload 
resulting from diverse factors. The excess of iron results in ROS formation, damaging 
several intracellular organelles, including mitochondria (Hershko, 2011). The observed 
effects are very close to what has been observed in rats subjected to a single injection of a 
massive dose of iron-dextran. In this case, mitochondria from treated rats showed decreased 
respiratory control ratio (Pardo Andreu, Inada et al., 2009). In another different model, rats 
diet-supplemented with iron lactate showed decreased ATP content in the liver and spleen, 
which was suggested to occur due to mitochondrial alterations (Fujimori, Ozaki et al., 2004). 
An interesting hypothesis is drawn from the work of Liang et al. The authors suggest that 
mitochondrial aconitase may be an important early source of mitochondrial iron 
accumulation in a model for experimental Parkinson's disease, with an oxidative 
inactivation of that enzyme occurring due to iron-mediated oxidative stress (Liang & Patel, 
2004). The role of iron in exacerbating the toxic effects of clinically used drugs is 
demonstrated, among other examples, by the fact that the iron chelator dexrazoxane 
protects cardiac myocytes against the toxicity of DOX (see above), via a mitochondrial 
mechanism (Hasinoff, Schnabl et al., 2003). 
Dioxins are environmental pollutants with a large impact on human health, being by-
products of incineration processes and of production of several chloro-organic chemicals 
(Sweeney & Mocarelli, 2000; Parzefall, 2002). 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is 
the best studied and the most toxic dioxin and data are vast describing clear direct effects of 
this compound on mitochondria. Several works identified the inhibition of the 
mitochondrial electron chain and increased generation of ROS as one mechanism by which 
TCDD exerts its toxicity in the heart (Nohl, de Silva et al., 1989) and liver (Stohs, Alsharif et 
al., 1991; Latchoumycandane, Chitra et al., 2002; Senft, Dalton et al., 2002). Senft et al. 
demonstrated that mitochondria are the source of TCDD-induced ROS, although the exact 
mechanism was still not clearly identified (Senft, Dalton et al., 2002). TCDD treatment 
resulted in an increased hydrogen peroxide release by the respiratory chain, although no 
alterations in mitochondrial superoxide dismutase or glutathione peroxidase were observed 
(Senft, Dalton et al., 2002). Interestingly, one week after treating mice with TCDD, coenzyme 
Q levels in the liver decreased, while activities of some of the mitochondrial complexes were 
increased (Shertzer, Genter et al., 2006). These and other results, led to the proposal that 
TCDD causes a defect on the ATP synthase in the liver, resulting in decreased ATP levels in 
the liver (Shertzer, Genter et al., 2006). Results in isolated rat hepatocytes confirmed the 
mitochondrial role on oxidative stress caused by TCDD (Aly & Domenech, 2009). It was also 
demonstrated by using a knock-out model that mitochondrial reactive oxygen production is 
dependent on the aromatic hydrocarbon receptor (Senft, Dalton et al., 2002) and causes 
direct damage to mtDNA (Shen, Dalton et al., 2005). Interestingly, TCDD induces apoptosis 
of human lymphoblastic T-cells, which do not express the aromatic hydrocarbon receptor; 
the mechanism being the triggering of mitochondrial-mediated intrinsic apoptotic pathway, 
mediated by calcium/calmodulin (Kobayashi, Ahmed et al., 2009). Another interesting 
possibility regarding the linkage between mitochondria and TCDD toxicity is the 
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perturbation of reproductive function by that dioxin (Wu, Li et al., 2001). Reported data 
indicate that low doses of TCDD cause increased oxidative stress, including depletion of 
antioxidant enzymes, in mitochondria and microsomal fractions from rat testis, which can 
alter the mitochondrial ability to supply energy to male germ cells (Latchoumycandane, 
Chitra et al., 2002). Mitochondrial interactions of TCDD and the possible carcinogenesis 
associated with dioxin exposure (Knerr & Schrenk, 2006; Jenkins, Rowell et al., 2007) 
(although others disagree, (Cole, Trichopoulos et al., 2003)) were also demonstrated to be 
related since TCDD causes mitochondrial depolarization, stress signaling and tumor 
invasion, besides altering calcium homeostasis (Biswas, Srinivasan et al., 2008). Besides, 
TCDD directly targets mitochondrial transcription and causes a mitochondrial phenotype 
which is similar to what is observed in rho0 cells (Biswas, Srinivasan et al., 2008). 
5. Mitochondrial liability in drug development and safety assessment 
Mitochondria are indeed, the crossroad for many cellular pathways, which explains the 
growing number of publications dealing with the mitochondrial role in cell life and death 
(Pereira, Moreira et al., 2009). As a result of the increased efforts focused on the role of 
mitochondria on a variety of human disorders as cancer, neurodegenerative, cardiovascular 
diseases, obesity, and diabetes, “mitochondrial medicine” emerged as a whole new field of 
biomedical research. Based on the recent developments in this field, a large effort is 
underway to understand how different molecules regulate or damage mitochondrial 
function, with the ultimate goal to improve human health. Two distinct and important 
mechanisms/endpoints by which drugs may inhibit mitochondrial function, can be 
considered (Fig. 3): a) direct interference with mitochondrial respiration/ATP synthesis 
(inhibition of respiratory complex activity, damage by ROS production, uncoupling activity, 
MPT induction) and b) inhibition of mtDNA synthesis. Regardless of the initial trigger, 
inhibition of ATP synthesis and bioenergetic failure of the tissue are severe manifestations of 
mitochondrial impairment. Several drugs or other xenobiotics can drive mitochondrial to an 
irreversible collapse via formation of the MPT pore leading to release of pro-apoptotic 
factors such as cytochrome c. Drugs that alter the normal equilibrium between pro-apoptotic 
and anti-apoptotic proteins, such as Bak/Bax and Bcl-2, can also induce mitochondrial 
failure and eventually cell death. Additional information for drug development and safety, 
as well for toxicity assessments may be achieved by the use of targeted approaches, affinity 
for overexpressed/subexpressed mitochondrial proteins during different diseases types, or 
selective mitochondrial accumulation of delocalized lipophilic molecules with positive 
charge and with different redox actions. Nevertheless, further investigation in these 
endpoints or guidelines of the molecular mechanisms of mitochondria-drug interaction will 
be needed for a better understanding of the mechanism of action involved in mitochondrial 
toxicity, allowing an improvement in the design of safer drugs or hazard assessment of 
xenobiotics with relevant human exposure. Notwithstanding these concerns, until now, 
several high-throughput techniques have been used to test and screen drug safety on 
mitochondrial function and could easily be studied to improve basic knowledge in drug 
development and associated toxicity. 
6. High throughput methods – the faster the better? 
High throughput methods have been developed with the ultimate objective of allowing 
company and research laboratories to perform large-scale screening or biochemical 
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analyses for a certain research or commercial objective. During many decades, low 
throughput methods were used in most research laboratories, including the Clark-type 
electrode or the tetraphenylphosphonium electrode to measure mitochondrial membrane 
potential or , respectively (Pereira, Moreira et al., 2009; Pereira, Pereira et al., 2009). 
Other low-throughput methods to investigate mitochondrial toxicity of several agents 
involved the measurement of activities of components of the mitochondrial respiratory 
chain by using polarographic, spectrophotometric or blue-native gel techniques 
(Barrientos, Fontanesi et al., 2009; Diaz, Barrientos et al., 2009). Although such methods 
are still in use in many laboratories worldwide (and in our own as well), profit-thirsty 
pharmaceutical companies require faster and cheaper methods to screen thousands of 
compounds per month in an attempt to uncover mitochondrial liabilities. For example, in 
the context of mitochondrial toxicity screening in drug development and safety, a 
fluorescence-based oxygen consumption assay was developed to analyze the ability of 
certain compounds to cause mitochondrial dysfunction.  This approach provides detailed 
and specific information about the possible mechanisms of toxicity based on 
measurements of respiratory states 3 and 4 by means of oxygen-sensitive probes. The 
advantages of this particular fluorescence method are the simplicity and large-scale of 
measurement, since it can be adapted to a plate reader system. The results can be 
visualized in real time and quantified in plate reader software (Hynes, Marroquin et al., 
2006). A later development included a combination of five high-throughput assays adding 
important information by identifying enzymes which can be target of the test compounds 
(Nadanaciva, Bernal et al., 2007). A set of immunocapture-based assays to identify 
compounds that directly inhibit oxidative phosphorylation can be used in the early 
evaluation of compound for clinical trials (Nadanaciva, Bernal et al., 2007). The same 
research group improved a method based on fluorescent probes for the study of oxygen 
consumption. The advantage is the possibility of screening several compounds 
simultaneously, being further up-scaled, automated and adapted for other enzyme- and 
cell-based screening applications (Will, Hynes et al., 2006). To test compounds that 
interfere with the synthesis of mitochondrial DNA or mtDNA-encoded proteins, a 96-well 
plate format method, that measures complex IV subunit 1, a protein encoded by mtDNA 
and complex V subunit 1, an nuclear DNA- encoded protein was developed (Nadanaciva, 
Dillman et al., 2010). 
The literature is getting richer in terms of new methods for high-throughput methods to 
evaluate mitochondrial function in different applications. When comparing fibroblasts 
from patients with mtDNA diseases with control subjects, a decrease in ATP production 
rate in muscle with normal OXPHOS enzyme activities was observed (Jonckheere, 
Huigsloot et al., 2010). This and other types of assays allow finding primary and 
secondary mitochondrial dysfunction, which can facilitate the search for genetic defects 
that can lead to mitochondrial diseases (Jonckheere, Huigsloot et al., 2010). Although in a 
smaller scale, the Seahorse Bioscience analyzer can be used for a multi-end point of cell 
and mitochondrial metabolism. In one particular study, the authors measured the 
mitochondrial function of renal proximal tubular cells observing that several 
nephrotoxicants alter mitochondria function before altering the basal respiration (Beeson, 
Beeson et al., 2010). The future will no doubt yield new fast and cost-effective high-
throughput methods to quickly investigate mitochondrial toxicity of xenobiotics in order 
not only to produce safer drugs but also to perform safety screenings on many 
compounds that humans are daily exposed to. 
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Fig. 3. Drugs or environmental xenobiotics can impair mitochondrial function through 
affecting different targets, including mitochondrial oxidative phosphorylation and ATP 
production. Oxidative stress and calcium overload increase the probability of irreversible 
mitochondrial failure via MPT pore, leading to release of pro-apoptotic factors such as 
cytochrome c. In addition, drugs that alter the ratio pro-apoptotic and anti-apoptotic 
proteins, such as Bak/Bax and Bcl-2, can also induce mitochondrial failure. OMM, Outer 
mitochondrial membrane; IMM, Inner mitochondrial membrane; NADH, Nicotinamide 
adenine dinucleotide reduced form; NAD+, Nicotinamide adenine dinucleotide oxidized 
form. 
7. Concluding remarks 
The question in the title suggests that doubts would still exist regarding the use of 
mitochondria as a biosensor for drug-induced toxicity. Hopefully, the present chapter 
provides enough evidence that mitochondria are a critical target in the toxicity of a wide 
variety of agents, ranging from clinically-relevant drugs, to environmental poisons. 
Moreover, it has been here demonstrated that failure of mitochondrial function originates 
several pathologies, which by its turn, contribute to amplify mitochondrial damage. 
Idiosyncratic drug reactions have also been proposed to involve mitochondria as well 
(Lucena, Garcia-Martin et al.). In fact, an individual who has a lower mitochondrial power 
may succumb first to the toxicity of mitochondrial-directed toxicants, even if the original 
mild mitochondrial alterations are asymptomatic. This is extremely critical for patients with 
diagnosed mitochondrial DNA diseases, who are in a high risk of suffering mitochondrial 
failure upon a second hit with a toxicant, either a clinically used drug or an environmental 
pollutant.  
The large number of mitochondrial targets, some of which were not even explored in this 
chapter, and the growing list of compounds presenting mitochondrial liabilities, clearly 
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answers our initial question. The field of mitochondrial pharmacotoxicology (Scatena, 
Bottoni et al., 2007) is now critical for many pharmaceutical companies and for a large 
number of research laboratories which work on basic toxicology (Chan, Truong et al., 2005; 
Dykens, Marroquin et al., 2007; Wallace, 2008; Nadanaciva & Will, 2009; Pereira, Moreira et 
al., 2009; Pereira, Pereira et al., 2009). Some for the sake of profit, others for the good of 
science itself, but all focusing on that little organelle that is in the spotlight right now. 
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